行情

FOLD

FOLD

Amicus
NASDAQ

实时行情|Nasdaq Last Sale

9.72
+0.26
+2.75%
交易中 14:45 11/22 EST
开盘
9.50
昨收
9.46
最高
9.74
最低
9.45
成交量
100.25万
成交额
--
52周最高
14.62
52周最低
7.11
市值
24.76亿
市盈率(TTM)
-6.1750
分时
5日
1月
3月
1年
5年

分析师评级

12位分析师的综合评级

买入

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

EPS

FOLD 新闻

  • Edited Transcript of FOLD earnings conference call or presentation 11-Nov-19 1:30pm GMT
  • Thomson Reuters StreetEvents.2天前
  • Coworking space takes aim at Lake Nona
  • American City Business Journals.2天前
  • How to Find Cheap Buy-Ranked Stocks Trading Under $10
  • Zacks.2天前
  • Is Amicus Therapeutics (NASDAQ:FOLD) A Risky Investment?
  • Simply Wall St..4天前

更多

所属板块

生物技术和医学研究
+1.63%
制药与医学研究
+0.74%

热门股票

名称
价格
涨跌幅

FOLD 简况

Amicus Therapeutics, Inc. is a biotechnology company. The Company is engaged in the discovery, development and commercialization of a set of treatments for patients living with devastating rare and orphan diseases. Its lead product, migalastat HCl is a small molecule that can be used as a monotherapy and in combination with enzyme replacement therapy (ERT) for Fabry disease. Its pipeline also includes SD-101, which is a product candidate in late-stage development, as a potential first-to-market therapy for the chronic, rare connective tissue disorder Epidermolysis Bullosa (EB). It is also leveraging its Chaperone-Advanced Replacement Therapy (CHART) platform technologies to develop ERT products for Pompe disease, Fabry disease, and potentially other lysosomal storage disorders (LSDs). The Company is also investigating preclinical and discovery programs in other rare and devastating diseases, including cyclin-dependent kinase-like 5 (CDKL5) deficiency.
展开

Webull提供Amicus Therapeutics, Inc.的股票价格,实时市场报价,专业分析师评级,深度图表和免费的股票新闻,以帮助您做出投资决策。